The role of SM22α in promoting hypoxia‐induced resistance in NSCLC through the IGF1R/PI3K/AKT pathway highlights its potential as a target to reduce therapeutic resistance in lung cancer. This evidence concerns the gene PIK3CD and non-small cell lung carcinoma.